Pan Gao

Pan Gao

Auto-generated profile, based on publicly available information

Pan Gao

Third Military Medical University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2009 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JCJianfei Chen
Jianfei Chen
MSMinbao Song
Minbao Song
SYShiyong Yu
Shiyong Yu
PGPan Gao
Pan Gao
YYYang Yu
Yang Yu
LHLan Huang
Lan Huang

3 December 2008 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
RGRui-Wei Guo
Rui-Wei Guo
HWHong Wang
Hong Wang
PGPan Gao
Pan Gao
MLMao-Quan Li
Mao-Quan Li
CZChun-Yu Zeng
Chun-Yu Zeng
LHLan Huang
Lan Huang
There is evidence to suggest that stromal interaction molecule 1 (STIM1) functions as a Ca2+ sensor on the endoplasmic reticulum, leading to transduction of signals to the plasma membrane and opening of store-operated Ca2+ channels (SOC). SOC have been detected in vascular smooth muscle cells (VSMCs) and are thought to have an essential role in the regulation of contraction and cell proliferation. We hypothesized that knockdown of STIM1 inhibits VSMC proliferation and suppresses neointimal hyperplasia. We examined the effect of the knockdown of STIM1 using a rat balloon injury model and cultured rat aortic VSMCs. Interestingly, knockdown of rat STIM1 by adenovirus delivery of small interfering RNA (siRNA) significantly suppressed neointimal hyperplasia in a rat carotid artery balloon injury model at 14 days after injury. The re-expression of human STIM1 to smooth muscle reversed the effect of STIM1 knockdown on neointimal formation. Rat aortic VSMCs were used for the in vitro assays. Knockdown of endogenous STIM1 significantly inhibited proliferation and migration of VSMCs. Moreover, STIM1 knockdown induced cell-cycle arrest in G0/G1 and resulted in a marked decrease in SOC. Replenishment with recombinant human STIM1 reversed the effect of siRNA knockdown. These results suggest STIM1 has a critical role in neointimal formation in a rat model of vascular injury. STIM1 may represent a novel therapeutic target in the prevention of restenosis after vascular interventions.

10 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSShuang Song
Shuang Song
PGPan Gao
Pan Gao
HXHang Xiao
Hang Xiao
YXYan Xu
Yan Xu
LSLian Yi Si
Lian Yi Si
Cardiomyocyte apoptosis is a common pathological alteration in heart disease which results in systolic dysfunction or sudden death. Klotho is a novel anti-aging hormone. We tested the effects of klotho on cell apoptosis in isoproterenol-treated cardiomyocytes. In BALB/c mice, cardiac injury was induced by subcutaneous injection of isoproterenol (5mg/kg, for 9days, sc). Klotho (0.01 mg/kg, every other day for 4days, ip) was administered to determine the changes in isoproterenol-induced apoptosis. Mouse heart was harvested at day 2, day 5, and day 9 after isoproterenol injection. Isoproterenol induced cardiac apoptosis and endoplasmic reticulum (ER) stress in a time-dependent manner. However, klotho partly reversed isoproterenol-induced cardiac apoptosis and ER stress. These same effects were observed in cultured cardiomyocytes. Furthermore, the results also showed that SB203580, a p38 inhibitor, and SP600125, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduced cardiomyocyte apoptosis and ER stress, however, klotho suppressed isoproterenol-induced activation of p38 and JNK. Taken together, these results indicated that cardioprotection by klotho was related to the attenuation of ER stress and ER stress-induced apoptosis, at least partly, through suppressing activation of the p38 and JNK pathway.

1 August 2014 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
XWXiao-Mei Wang
Xiao-Mei Wang
SSShuang-Shuang Song
Shuang-Shuang Song
HXHang Xiao
Hang Xiao
PGPan Gao
Pan Gao
XLXue-Jun Li
Xue-Jun Li
LSLiang-Yi Si
Liang-Yi Si
Fibroblast growth factor 21 (FGF21) is a powerful endocrine hormone modulating glucose and lipid metabolism and represents a promising drug for type 2 diabetes. The present study was to determine the effect of FGF21 on high glucose-induced damage and dysfunction in endothelial cells. The protein expression of β-klotho was examined in human umbilical vein endothelial cell (HUVECs) using immunofluorescence and Western blotting. HUVECs were cultured in medium with normal glucose (NG), high glucose (HG) and HG + FGF21 (30 nM). Cell viability, migration, reactive oxygen species (ROS), malondialdehyde (MDA), superoxide dismutase, nitric oxide (NO) production, intracellular cyclic guanosine monophosphate (cGMP) and endothelial nitric oxide synthase (eNOS) phosphorylation at Ser-1177/Ser-633 sites were measured. β-klotho, the anchor protein of FGF21, is expressed in HUVECs. Administration of FGF21 prevented HG-induced impairment of cell viability, migration, oxidant stress, NO production and intracellular cGMP levels in HUVECs. FGF21 also rescued HG-induced decrease of eNOS phosphorylation at Ser-1177 and Ser-633. HG and FGF21 had no effects on eNOS phosphorylation at Ser-617 and Thr-495. Inhibition of AMP-activated protein kinase (AMPK), but not Akt or Ca(2+)/calmodulin-dependent protein kinase II, abolished the protective effect of FGF21 on eNOS phosphorylation at Ser-1177. The protective effect of FGF21 on eNOS phosphorylation at Ser-633 was also abolished by inhibition of AMPK but not by Akt or cAMP-dependent protein kinase A. Our results provide the first evidence that FGF21 protects against high glucose induced cell damage and eNOS dysfunction in an AMPK-dependent manner in HUVECs, and suggest that FGF21 may be a promoting therapeutic agent for vascular complications in diabetes.

17 December 2012 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
PGPan Gao
Pan Gao
XWXiao-Mei Wang
Xiao-Mei Wang
DQDei-Hui Qian
Dei-Hui Qian
ZQZe-Xue Qin
Ze-Xue Qin
JJJun Jin
Jun Jin
LSLiang-Yi Si
Liang-Yi Si
The aim of this study was to explore meprinα-mediated transactivation of the epidermal growth factor receptor (EGFR) and reactive oxygen species (ROS) production in macrophages. Accelerated atherosclerotic lesions were established by administration of a high-fat diet in apolipoprotein E-deficient (apoE–/–) mice. Lentiviral overexpression of meprinα in the thoracic aortic artery during plaque formation enhanced intra-plaque macrophage induction of ROS as well as formation of atherosclerotic plaques, whereas AG1478 (specific inhibitor of the EGFR) treatment exerted the opposite effect. A meprinα inhibitor abrogated EGFR activation in mice. In cultured J774a.1 macrophages, oxidized low-density lipoprotein (OxLDL) increased ROS formation and EGFR activation through a ligand [heparin-binding epidermal growth factor-like growth factor (HB-EGF)]-dependent pathway. However, a meprinα inhibitor or specific siRNA inhibited ROS production and EGFR activation. Recombinant mouse meprinα enhanced OxLDL-stimulated production of ROS and induced HB-EGF. Inhibition of p38 mitogen-activated protein kinase by SB203580 decreased OxLDL-stimulated production of ROS. Conversely, inhibition of meprinα or PI3K-Rac1 inhibitors also decreased p38 activity in OxLDL-stimulated macrophages. In addition, inhibition of meprinα reversed OxLDL-stimulated activation of PI3K. Meprinα promotes OxLDL-induced plaque formation and ROS release by transactivation of the EGFR, followed by activation of the PI3K/Rac1/p38 pathway.

1 May 2009 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
JCJianfei Chen
Jianfei Chen
LHLan Huang
Lan Huang
MSMinbao Song
Minbao Song
SYShiyong Yu
Shiyong Yu
PGPan Gao
Pan Gao
JJJun Jing
Jun Jing
Object: The receptor for advanced glycation end products (RAGE) may play an important role in inflammatory processes and endothelial activation, likely to accelerate the processes of atherosclerosis, especially in patients with diabetes. The factors that regulate the expression of RAGE are not completely clear. C-reactive protein (CRP) is identified as a key proinflammatory cytokine in patients with atherosclerosis. Atherosclerosis also induces reduction and dysfunction of endothelial progenitor cells (EPCs), a main cell type for vascular repair. Therefore, we tested the hypothesis that CRP can regulate RAGE expression and alter antioxidant defenses in EPCs. Methods and Results: EPCs, isolated from bone marrow, were cultured in the absence or presence of lipopolysaccharide-free CRP (5, 10, 15, 20, and 50 μg/mL). RAGE protein expression was measured by flow cytometric analysis and Western blot. RAGE messenger RNA expression was detected by polymerase chain reaction. Reactive oxygen species (ROS) were analyzed using the ROS assay kit. A spectrophotometer was used to assess superoxide dismutase and glutathione peroxidase activity, and polymerase chain reaction was used to test messenger RNA expression of superoxide dismutase and glutathione peroxidase. Apoptosis was evaluated by Annexin V immunostaining. Coculturing with CRP caused a significant upregulate expression of RAGE in EPCs, increased ROS production, altered antioxidant defenses, and induced EPC apoptosis. In addition, these effects were attenuated during blocking RAGE protein expression by small interfering RNA. Conclusions: CRP at concentrations known to predict cardiovascular event may serve to impair EPC antioxidant defenses for upregulating the expression of RAGE and promote EPC sensitivity toward oxidative stress-mediated apoptosis. These data further support a direct role of CRP in the development and/or progression of atherosclerosis.